{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:06:52Z","timestamp":1785330412612,"version":"3.55.0"},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,3,29]],"date-time":"2006-03-29T00:00:00Z","timestamp":1143590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Novel activation products that are stable and minimally susceptible to in vitro artefacts have recently been described in the classical complement pathway. The present study assessed circulating levels of these products, i.e., covalent complexes between the recognition molecule of the classical pathway (C1q) and activated C4, in plasma samples from patients with rheumatoid arthritis (RA) to establish the relationship between these levels and the clinical and immunologic parameters in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>C1q\u2013C4 levels were measured in plasma samples from 41 patients with active RA and 43 patients with inactive RA. These levels were related to other complement activation products and to disease activity according to the Disease Activity Score in 28 joints (DAS28), using Spearman's rank correlations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>C1q\u2013C4 plasma levels were significantly higher in patients with active RA as compared with patients with RA in clinical remission (median 3.3 arbitrary units [AU], range 0.4\u201313.4 versus 1.7 AU, range 0.2\u20135.5; <jats:italic>P<\/jats:italic> = 0.0001), suggesting that activation of the classical complement pathway reflects disease activity. This was supported by a significant correlation between C1q\u2013C4 levels and the DAS28 (r = 0.398, <jats:italic>P<\/jats:italic> = 0.0002). Levels of other complement activation products, such as activated C4 (C4b\/c), were also significantly elevated in patients with active disease compared with patients with inactive disease (<jats:italic>P<\/jats:italic> = 0.03), and were correlated with C1q\u2013C4 levels (r = 0.329, <jats:italic>P<\/jats:italic> = 0.002). Levels of C1q\u2013C4 complexes were higher in synovial fluid samples than in plasma samples from the 4 patients tested.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Systemic complement activation via the classical pathway in patients with RA correlates with disease activity. These results indicate that C1q\u2013C4 complexes may be used as a biomarker for RA.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.21729","type":"journal-article","created":{"date-parts":[[2006,3,30]],"date-time":"2006-03-30T02:48:33Z","timestamp":1143686913000},"page":"1143-1150","source":"Crossref","is-referenced-by-count":45,"title":["Evaluation of classical complement pathway activation in rheumatoid arthritis: Measurement of C1q\u2013C4 complexes as novel activation products"],"prefix":"10.1002","volume":"54","author":[{"given":"Diana","family":"Wouters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre E.","family":"Voskuyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmeralda T. H.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben A. C.","family":"Dijkmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Erik","family":"Hack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,3,29]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.48.4.302"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1988.tb17695.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200424895"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780341209"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780291108"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780281003"},{"key":"e_1_2_5_8_2","first-page":"521","article-title":"C1 inactivator\u2010C1s complexes in inflammatory joint disease","volume":"53","author":"Inman RD","year":"1983","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02206833"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.3.299"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.1.454"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.19.8955"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108399"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.38.1.1"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107949"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.52.11.795"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02207676"},{"key":"e_1_2_5_18_2","first-page":"33","article-title":"Complement activation by 19S IgM rheumatoid factor: relationship to disease activity in rheumatoid arthritis","volume":"13","author":"Robbins DL","year":"1986","journal-title":"J Rheumatol"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780250208"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270108"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200105)44:5<997::AID-ANR178>3.0.CO;2-C"},{"key":"e_1_2_5_22_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4049\/jimmunol.113.1.9","article-title":"Interaction of C\u2010reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q","volume":"113","author":"Volanakis JE","year":"1974","journal-title":"J Immunol"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1997.4516"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02274887"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2004.12.018"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780241012"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(88)90169-1"},{"key":"e_1_2_5_30_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4049\/jimmunol.157.1.473","article-title":"CRP\u2010mediated activation of complement in vivo: assessment by measuring circulating complement\u2010C\u2010reactive protein complexes","volume":"157","author":"Wolbink GJ","year":"1996","journal-title":"J Immunol"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(93)90240-8"},{"key":"e_1_2_5_32_2","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4049\/jimmunol.127.2.648","article-title":"Purification and radiolabeling of human C1q","volume":"127","author":"Tenner AJ","year":"1981","journal-title":"J Immunol"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108708"},{"key":"e_1_2_5_34_2","first-page":"93","article-title":"Immune complex mediated activation of the classical complement pathway","volume":"84","author":"Borsos T","year":"1989","journal-title":"Behring Inst Mitt"},{"key":"e_1_2_5_35_2","first-page":"449","article-title":"IgA containing immune complexes in rheumatoid vasculitis and in active rheumatoid disease","volume":"12","author":"Westedt ML","year":"1985","journal-title":"J Rheumatol"},{"key":"e_1_2_5_36_2","first-page":"259","article-title":"Detection of immune complexes and their relationship to rheumatoid factor in a variety of autoimmune disorders","volume":"46","author":"Pope RM","year":"1981","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_5_37_2","first-page":"54","article-title":"IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy","volume":"43","author":"Scott DG","year":"1981","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.42.2.147"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.51.10.1123"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.21729","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.21729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T21:17:20Z","timestamp":1698787040000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.21729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,29]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1002\/art.21729"],"URL":"https:\/\/doi.org\/10.1002\/art.21729","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,29]]}}}